Clinical trials: Retinal Vein Occlusion
Macular Edema, Retinal Vein Occlusion
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion.
- Trial name
- NCT01027650
- Testing
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 121 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal…
- Trial name
- NCT01449682
- Testing
- Ozurdex
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Retina Macula Institute
Central Retinal Vein Occlusion
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years.
- Trial name
- SCORE2 (NCT01969708)
- Testing
- aflibercept, bevacizumab
- Where
- 72 sites in United States
- Volunteers
- 362 people
- Sponsor
- The Emmes Company, LLC
Choroidal Neovascularization, Age-related Macular Degeneration
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV)…
- Trial name
- NCT00379795
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 853 people
- Sponsor
- Genentech, Inc.
Macular Edema, Central Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Conditions
- Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion
- Trial name
- COMINO (NCT04740931)
- Testing
- Faricimab, Aflibercept
- Where
- 194 sites in United States, Argentina and 20 more
- Volunteers
- 729 people
- Sponsor
- Hoffmann-La Roche
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema
Cool vs Room-temperature Artificial Tears
Background and Objective: To evaluate the efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection (IVI) ocular discomfort.
- Conditions
- Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema
- Trial name
- NCT05832996
- Testing
- Refresh Plus Preservative-free Lubricant Eye Drops
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
To see if Lucentis 0.5mg combined with Targeted Pan Retinal photocoagulation will decrease the total number of intravitreal injections in a year for ischemic central retinal vein occlusion, hemi-retinal vein occlusions and branch…
- Trial name
- WAVE (NCT01710839)
- Testing
- 0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Charles C Wykoff, PhD, MD
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion…
- Trial name
- CRYSTAL (NCT01535261)
- Testing
- Ranibizumab 0.5 mg/0.05 ml
- Where
- 78 sites in Australia, Austria and 16 more
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Minocycline to Treat Central Retinal Vein Occlusion
Background: Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye.
- Trial name
- NCT01468844
- Testing
- Minocycline, Bevacizumab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusion, Diabetic Macular Edema
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or…
- Trial name
- Molokini (NCT02245516)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0% Ophthalmic Suspension
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Macular Edema, Retinal Vein Occlusion
Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Central and branch retinal vein occlusions are major causes of visual loss. Hemorrhage and capillary nonperfusion, when they involve the macula, can contribute to visual loss, but the major cause is macular edema.
- Trial name
- LVO (NCT00407355)
- Testing
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Peter A Campochiaro, MD
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
To measure the pro-permeability factors in the aqueous humor of patients with persistent/recurrent macular edema after an injection of Ozurdex.
- Trial name
- ORVO (NCT01790685)
- Testing
- dexamethasone implant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company
Macular Edema, Retinal Vein Occlusion
Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina
This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
- Trial name
- FAVOR (NCT00770770)
- Testing
- Fluocinolone Acetonide
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alimera Sciences
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Macular Edema, Retinal Vein Occlusion
Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.
- Trial name
- NCT01618266
- Testing
- dexamethasone intravitreal implant
- Where
- France
- Volunteers
- 375 people
- Sponsor
- Allergan